Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares iBoxx $ High Yield Corporate Bond ETF (HYG) vs Mesoblast Limited (MESO) Price & Performance

iShares iBoxx $ High Yield Corporate Bond ETFTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

iShares iBoxx $ High Yield Corporate Bond ETF vs Mesoblast Limited — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.65, while Mesoblast Limited trades at $16.38 (market cap $2.17B). Which is the better fit depends on your goals.

HYGMESO
Sector
Fixed IncomeTechnology
52-Week High
$81.32$20.96
52-Week Low
$78.72$12.88
Market Cap
$2.17B
Enterprise Value
$2.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares iBoxx $ High Yield Corporate Bond ETF

HYG trades at $79.68, up slightly by 0.04% today, but technical indicators signal a bearish trend with moving averages and overall signals pointing to selling pressure. The fund has declared dividends for 2026, including $0.37 and $0.41 payouts, amid a backdrop of high bond market volatility and investor caution. Recent news highlights elevated put volume and bearish bets against high-yield bonds, reflecting broader market uncertainty.

The outlook for HYG is cautious due to bearish technicals and macroeconomic headwinds like potential Fed rate hikes. Risks include interest rate sensitivity and inflation pressures, but the dividend yield may attract income-focused investors. Wall Street sentiment is mixed, with institutional flows into bond ETFs offering some support amid prevailing risks.

Mesoblast Limited

MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.

Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares iBoxx $ High Yield Corporate Bond ETF

HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.

Read more on HYG

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO